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Abstract
In this paper the results of a survey into the organizational and managerial factors influencing outcome
in industrial pharmaceutical R&D are presented. The study consists of structured interviews with
research directors of fourteen large and medium sized pharmaceutical companies, combined with quan-
titative and qualitative questionnaires. A systems theoretic approach has been used to postulate the
relevant entities and the relations between them. The basic assumption has been that pharmaceutical R&D
can be viewed upon as a conversion process in which information (knowledge) and R&D-input (chemical
compounds) are converted into R&D-output (chemical compounds with information, namely about therapeutic
efficacy and possible side-effects on patients), while control of this conversion process is exercised
by R&D-throughput (scale, structure, management control, communication and coordination). The main
conclusion is, that a number of managerial and organizational differences can be distinguished, in terms
of speeding up product development and adjustment to market needs, dividing the outstanding from the
average innovative companies. The analyses suggest that the motivation of scientific staff is one of the
major success parameters. Also the perceived quality of coordination in terms of planning and evaluation
is an important predictor of success in pharmaceutical R&D. The positive effect of coordination however,
seems to be partly lowered by too frequent meetings. For three of the larger companies in the sample the
data suggest that at R&D-expenditures of 12-15 percent of sales the companies has to put so much effort
in the Development process, especially in large scale clinical trials, that the innovative potential
could become at risk.
INTRODUCTION
Drug regulation and pricing have put strong pressure on the cost-benefit
ratio of industrial pharmaceutical R&D. The increasing governmental regula-
tory demands regarding efficacy and safety of drugs have extended the R&D-
process considerably. In the sixties in general the period between the
finding of the 'lead' - a chemical compound with assumed therapeutic effi-
cacy- and the introduction on the prescription drug market was about five
years. Nowadays it takes more than ten years to do the pharmaceutical
research, the toxicological and clinical testing needed, to bring a 'lead'
to the market. The R&D-expenses have increased accordingly. Because a
patent is submitted on the 'lead', while earnings start only ten years
later, the effective patent protection time fell back from an average of
thirteen years around 1965 to eight to ten years in the middle of the 1980s
[Redwood, 1987]. Taking into account the policy of most national govern-
ments to reduce medical costs by influencing drug prices, for instance by
stimulating the prescription of less costly generic drugs, it is clear that
increasing pressure has been put on pharmaceutical industry. In this paper
the results will be presented of a study in fourteen large and medium sized
companies in order to determine some important organizational and mana-
gerial factors influencing success, in terms of speeding up product
development and better adjustment to market needs, in industrial pharma-
ceutical R&D.
In this paper at first the question will be answered whether or not 'econo-
mjes of scale' occur in pharmaceutical R&D? Taggart [1992] refers to
studies based upon figures of the 1950s in which 'diseconomies of scale'
were established substantially below the largest R&D-effort. Later research
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in the 1970s reported constant or increasing returns to R&D-scale. Taking
into account the increased pressure on pharmaceutical R&D, it is even more
interesting	 to establish the present-day situation. Further the results of
a multivariate analysis, using the neural network method, will be dis-
cussed, providing a better understanding of the relative importance of the
different factors influencing outcome. For the eight larger companies,
which spend more than 	 375 million dollar on R&D in 1991,
	 the annual figures
of the pharma sales,
	 R&D-expenditures and number of patents submitted, were
collected for the period 1985 till 1991. On the basis of these data a time
series analysis was executed. The results are also presented in this paper.
METHODS
In this research project a systems theoretic approach has been used to
postulate the relevant entities and the relations between them. The basic
assumption has been that pharmaceutical R&D can be viewed upon as a conver-
sion process in which information (knowledge) and R&D-input (chemical
compounds) are converted into R&D-output (chemical compounds with informa-
tion, namely about	 therapeutic efficacy and possible side-effects on
patients), while control of this conversion process is exercised by R&D-
throughput	 (scale,	 structure,	 management control,
	 communication and
coordination). At first the R&D-process will be examined in more detail,
then the variables used in this paper will be discussed.
The industrial pharmaceutical R&D-process
In figure 1 the different phases in the industrial pharmaceutical R&D-
process are	 presented using the model of the double unit cell [van Engelen
1989], a combination	 of a control situation and a value	 chain as described
by Porter [1985].
Figure 1
In the discovery phase the research concepts are elaborated and 5 to 10,000
chemical compounds are synthesized on a laboratory scale and screened for
therapeutic	 activity in a biological or animal model. This phase has an
average duration of one to two years, but sometimes it can take many years.
The phase	 ends with the discovery of the 'lead'. The pharmacological
development phase	 starts with further pharmacological screening and
characterization of the active substance in 20 to 50 compounds. Pharmacoki-
netical research into degradation speed and acute and subacute toxicity
along with	 mutagenicity tests are done. Then follows the synthesis of the
active substance at	 the technical level of the 10 to 15 compounds which go
further in	 clinical	 testing. Patenting is carried out in this phase, which
has an average duration of 2 to 	 3 years. In the clinical research phase I
dose-effect	 relationships, duration of effects and side effects are tested
in 50 to 100 healthy volunteers. In phase II the first 	 controlled clinical
trials are carried out on a total of 200 to 400 patients with approximately
5 compounds. In phase III the	 controlled trials continue with only one
compound. The double	 blind randomized clinical trials are executed among a
great number of patients in (academic) hospitals to demonstrate therapeutic
efficacy and to establish contra-indications, side effects with a relative-
ly high incidence and optimal dosage. In recent years the larger firms work
more and more with	 parallel development. So, at the	 same time that the
clinical trials are	 executed the long scale biological 	 testing for chronic
and subchronic toxicity continues and the up-scaling for production of the
;rug starts. This phase takes 3 to 4 years and ends with the presentation
J the relevant pharmacological and toxicological data and the results of
he clinical trials to the authorities. The registration phase involves the
:ontrol of the test dossiers by the authorities for approval of the drug on
the market and takes approximately 2 years. During the registration period
the designing and building of the production facilities and manufacturing
process continues, the marketing plan is formulated and the training of the
sales force starts. In this way the larger pharmaceutical companies are
able to launch a new drug within months after registration. After launch
the post marketing surveillance starts to trace side effects of drugs with
low and moderate incidence which were not discovered during clinical
testing [Fitzgerald 1992,
	 Taggart 1992 and 1993 and this study].
Operationalization of variables
In table 1 an outline is
	 given of the operationalization of the predictor
(through puts) and the criterion variables (output).
Table I
For the assessment of the variables personnel control and coordination
Likert-scales are used.
	 The scales for the assessment of research manage-
ment are based upon the
	 questionnaires used in the 'Philips Natlab', the
others were newly developed. After the data collection the internal
consistency of the scales was calculated. Cronbach's a being sufficiently
high (> .75) to warrant confidence in the consistency [Swanborn, 1987]. The
multivariate analyses are done with the neural network method. It utilizes
an intricate fitting method, which uses the iterative steepest descent
technique to approach the minimum error solution. It is developed for usage
in cases in which other 	 numerical modelling methods perform poorly, due to
insufficient or singular data [Hoptroff, 1991]. The method is based upon
the division of the data in a model set and an independent test set. In
this study the data of	 two companies were used for the independent test
set. Changing model and test set did not influence the outcome of the
calculations significantly. The parameters measured at interval and ordinal
level are analyzed by use of non-parametric ranking methods.
Data collection
In 1992 the research laboratories of the ten largest Anglo-american and
'continental' pharmaceutical companies (average sales per company in 1991:
4.5 billion dollar) were approached for this study. In addition ten
research laboratories of medium sized European companies (average sales: 2
billion dollar) were selected. The study consists of structured interviews
with the Directors of the Research and/or Development and Clinical Research
Divisions (mostly Members of the Board), combined with quantitative and
qualitative questionnaires, regarding personnel, budget and research pol-
icy. Seven large and seven medium sized companies agreed upon participa-
tion. Two large and two medium sized companies only supplied general
information regarding sales, R&D-staff and research management, while in
ten companies also specific information regarding structure, management co-
ntrol and communication could be obtained. In total 22 interviews were held
and 38 questionnaires returned (response rate of 65%). The patent analysis
revealed the representativity of the companies in the sample. Twentyfive
percent of the pharmaceutical patents submitted with a European priority
from 1985 till 1991 originated from one of the companies in this study.
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RESULTS
Economies of scale
It can be expected that the total R&D-expenditures and the pharma sales in
a given year are more or less related, because the annual R&D-budget is -at
least- partly based on the volume of sales in the previous year. In order
to get an idea about this relation the total R&D-expenditures in 1991 are
compared with the pharma sales in the same year of the companies under
study. As shown in figure 2 a S-curve emerges (r 2 =.94—', N=14). Apparently
larger pharma sales are only partly converted into higher R&D-expenditures.
The curve rises until the pharma-sales reach approximately 4 billion
dollar. After that the R&D-expenditures rise only moderately, from about
700 to a maximum of 875 million dollar, while the pharma-sales rise to
approximately 7 billion dollar.
Figure 2 Sales of pharmaceutical products and the total R&D-expenditures
per company in 1991 (both in million US dollar)
Sources: Annual reports of the pharmaceutical companies at issue and
Taggart (1993)
In order to examine the efficiency of the R&D-process in terms of absolute
R&D-output in relation to scale, the average annual R&D expenditures of
1988 till 1991 are plotted against the average number of pharmaceutical
patents submitted in the same period. As shown in figure 3 an exponential
equation emerges (r 2 =.87 ** , N=14) starting at around 180 million dollar,
going up to around 700 million dollar, while the annual number of patents
rises from 10 to 175.
Figure 3 Average number of patents for new chemical compounds submitted
world wide versus the average annual R&D expenditures (in million US
dollar) per company from 1988 till 1991
Sources: World Patent Index and Taggart (1993)
In order to examine whether a difference in R&D-efficiency could be
established between larger and smaller companies a t-test was done. The
larger companies (sales volume above 3 billion US dollar, N=7) in this
study not only submitted more patents in the absolute sense than the
smaller companies (less than 2.5 billion US dollar), but also related to
their R&D-investment (15 versus 9 patents per 100 million dollar R&D-
expenditures * ). Also the number of therapeutic areas in which the different
pharmaceutical companies are doing research increased with the size of the
R&D-expenditures, from 5-6 therapeutic areas in the smaller companies till
8-9 in the larger ones.
Figure 4 Length of the R&D-process (in years) versus the number of R&D-
staff per company in 1991
Sources: see figure 2
The length of the R&D-process is one of the most important R&D-parameters
2-tailed significance *** p < .001, ** p < .01	 p < .05
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influencing the profitability of a pharmaceutical company. The better a
company succeeds in reducing the length of the R&D-process, the more
successful it will be. Therefore in figure 4 the length of the R&D-process
is plotted against the total number of R&D-staff world wide. There proves
to be a significant correlation, the more scientific and analytical
personnel is appointed, the shorter the duration of the R&D-process
(r2 =.75 . , N=11). At first the length of the R&D-process is dropping fast
from 15-16 years at around 1500 R&D-staff members to 11-12 years at 3000
staff members, then the curve approaches to a R&D-length of around 10 years
at around 5000 R&D-staff members.
Multivariate analyses
In order to get a better understanding of the association of the different
managerial and organizational factors in relation to the world wide sales
of pharmaceutical products, in table 2 the results of the modelling
sessions by means of the neural network are presented. At first a modelling
session was executed including all predictor variables. The parameter which
contributed least was omitted. After the first session resources control,
after the second session structure and after the third external communi-
cation, was omitted. The results of the fourth modelling session are pres-
ented in table 2. The volume of the R&D-expenditures proves to have the
largest impact on pharma sales, followed by the perceived quality of
personnel control (human resource management), R&D-process communication
and coordination.
Table 2
In table 2 the results of the modelling session without R&D-expenditures
are presented between brackets. The model and test set fit being around 15%
and 30% lower than with the R&D-expenditures included in the model. The t-
value of personnel control rises, while those of R&D-process communication
and perceived quality of coordination stay relatively constant. Because of
the ordinal type of most of the scales used in this study, the 'strength of
the association' of the different R&D-parameters with sales has no uniform
interpretation. Therefore only the direction of the association is dis-
cussed here. If the direction of an association is positive it may indicate
that a company which pays less attention to that factor may consider inten-
sifying it. If the relationship is negative, it may indicate an overe-
xposition in at least part of the companies studied. The association of the
R&D-expenditures, personnel control and coordination with pharma sales is
positive. The association with structure (percentage of research in the
total R&D-process), resources control and communication is negative.
For the eight larger companies in the sample, which spend 375 million
dollar or more on R&D in 1991, the association of the R&D-expenditures as
percentage of pharma sales and the number of patents submitted in the
period of 1985 till 1991, was calculated. For four companies a model could
be drawn up. In three cases both the model and the test set fit were above
85%. In one case the test set fit was very good (above 95%), but the model
fit was significantly lower (around 60%). For three companies the data
indicate an optimum of the number of patents submitted at a R&D-investment
of 12-15 percent of pharma sales. In the fourth company the number of
patents goes up exponential with higher R&D-investment. The model stops
just below 13 %, so a deflection at a higher percentage is possible.
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DISCUSSION AND CONCLUSIONS
Economies of scale
There proves to be a relation between the R&D expenditures and the sales of
pharmaceutical products of the companies in this study, the larger com-
panies spending more than the smaller ones. This was expected because the
annual R&D-budget is partly based on the sales in the previous year. The
increase of the R&D-expenditures with the size of the company goes hand in
hand with the increase in the number of patents submitted world wide. How-
ever, if we focus on the R&D-expenditures as a percentage of sales, the
larger firms spend relatively less than the smaller ones. Also the number
of therapeutic areas is larger and the duration of the R&D-process is
shorter in the larger companies. Taking into account that also the relative
investment per patent is lower in the larger companies, empirical confir-
mation has been found for the theoretical supposition that 'economies of
scale' would appear in pharmaceutical R&D.
The shorter duration of the R&D-process in the larger companies can of
course mainly be attributed to the greater size of the R&D-staff and
budget. In the structured interviews some Research Directors gave as a
further explanation, that larger companies have more possibilities for
parallel development. It is relatively easy to shift R&D-staff between pro-
jects. According to the model developed by Grabowski and Vernon [1987] each
year an innovative drug can be launched earlier, counts for three years of
additional patent protection. For, as a drug has been longer on the market,
the chance increases that a new innovative drug will push it from the
market. Or, as a research director claimed in one of the structured
interviews: 'Each day a potential best selling drug will reach the market
earlier, yields 200,000 dollar for the company'. For smaller companies it
will become more and more difficult to meet the strict requirements of the
authorities regarding 'quality control' of the R&D-process. The recent in-
tegration process in pharmaceutical industry, expressed by a number of
merges, strategic alliances and joint ventures, joint research and joint
marketing [for instance Elfferich, 1992] appears to be justifiable, also
from the viewpoint of the efficiency of the R&D-process.
The curve in figure 3, linking the R&D-expenditures and the number of
patents submitted, starts at around 180 million US dollar, which could
suggest that such an amount is minimally needed to keep up the whole
pharmaceutical R&D-process. This amount corresponds with the bottom line of
the following, very rough calculation based upon the information of the
Research Directors. For the Research and Development of a new drug 200 to
300 million dollar is needed. Roughly speaking, one in every four drugs is
successful on the prescription drug market and once in every four years a
pharmaceutical company develops a successful drug. Taking into account that
the successful drugs count for the profitability of a pharmaceutical
company, it can be calculated that a minimum annual R&D-expenditure of 200
million dollar is needed to keep up the innovative potential (200 million
dollar per new drug times four to get a successful drug divided by four
years). A further qualitative judgement of the data suggests that a minimum
investment of 50-60 million dollar a year is needed to keep up in-house
innovative research. Only one division of a conglomerate spends less on
Research, the Research Director indicating that discovery was partly done
in another Division and incrementing was the main task. The data suggest
that for Development the threshold lies more than twice as high than for
Research, namely at about 110-125 million dollars a year. Three smaller
companies reporting expenditures of around this size. However, further
research is needed to confirm these data systematically.
Multivariate analyses
The R&D-expenditures
	 appear to explain most of the variance in pharma
sales. From the results in table 2 can be seen that especially personnel
control and R&D-process communication and, although to a lesser extent,
coordination are the
	 most important organizational and managerial parame-
ters influencing pharma sales. A relatively flat organization like a R&D-
laboratory however, provides less possibilities for promotion in terms of
responsibility. Some Research Directors suggested in the structured
interviews that in such an environment, remuneration by means of scientific
promotion, incentives like shares or options for extra-ordinary achie-
vements and publications as one of the aspects in salary determination,
could be of great importance to keep scientific personnel motivated.
The pharmaceutical R&D-process, executed in different laboratories, often
situated in different countries, needs strong coordination, in order to
connect the different phases in the R&D-process as smooth as possible.
Therefore it is not
	 surprising that coordination in terms of perceived
quality of planning and evaluation has a positive impact on pharma sales.
On the other hand the negative association of the factor R&D-process
communication with sales indicates that, at least in part of the companies,
the communication seems to be somewhat exaggerated. Indeed some of the
Research Directors reported in the structured interviews that time was lost
with too frequent meetings. As one of the Research Directors stated: 'It is
not quite clear whether the project teams have speeded up the R&D-process.
Indeed, the communication between the different phases in the R&D-process
has been improved and also with marketing and production, but the number of
meetings has increased accordingly.'
The results show that the association of structure with pharma sales is
minimal. If the company spends a higher percentage of the R&D-budget on
Research the consequences seem to be slightly negative. Inverted it means
that a weak positive correlation was found with the percentage of the R&D-
budget spend on preclinical and clinical Development. But the association
is so small that it does not supply a basis for management decisions.
Resources control,	 reflecting the flexibility in the allocation of
resources, is not predicted by the model as a positive factor influencing
pharma sales. Also the strength of the association with pharma sales is
very limited. This is surprising, because flexibility is often mentioned as
a major factor in rising productivity. Apart from the multi-purpose and
therefore often indistinct use of the term flexibility (see for instance
Volberda, 1992), the reason for this finding can be that flexibility may
stand on bad terms with human resource management. The positive effects of
flexibility might be overruled by the negative effects on the motivation of
scientific personnel. Especially in research it can be very demotivating to
be drawn away from a topic. As one of the Research Directors stated: ' Most
pharmaceutical companies concentrate their efforts on . a few therapeutic
areas. Of course this is inevitable, because of the huge investment needed
for the preclinical and clinical development of a new drug. But the freedom
to give the scientists in basic research the possibility to, at least
partly, concentrate on own ideas, has proven to lead to several new prod-
ucts, which otherwise never would have been invented.'
An indication that this is the case could be, that univariate analysis has
pointed out that personnel and resources control are not correlated in the
study sample.
For three of the larger companies an optimum curve arises when a time
series analysis is made of the relative annual R&D-investment and the
number of patents submitted in the same period. For a fourth company an
exponential curve arises. For these companies the volume of sales was con-
stantly rising in the period under study. Also the R&D-expenditures were
rising in the absolute sense, although sometimes faster and sometimes
slower than the volume of the pharma sales. As was mentioned in a former
article of the authors (Omta et al 1993), the number of patents submitted
by the larger companies stayed constant for most companies or was only
slightly rising in the period under study. This in clear contrast with the
smaller companies which submitted significantly more patents at the end of
the period. This is probably due to a further concentration of efforts to a
limited number of therapeutic areas, as was often mentioned in the struc-
tured interviews. Also a change in the patent strategy of the larger com-
panies could be involved, in that sense that companies wait longer before
patents are submitted in order to reduce costs and to shorten the period
between patent submittance and market launch, in order to prolong the
effective patent protection period.
The modelling parameter 'number of patents' only concerns the discovery
part, the first two to three years of the R&D-process. Two third to three
quarter of the R&D-expenditures however, is spent on the Development-pro-
cess. The Research Directors indicated that in recent years especially the
costs of the large scale clinical trials went up rapidly. Research and
Development are coupled in time, in that sense that research efforts
leading to potential interesting patents will risen the Development costs
in the succeeding years. Therefore the results presented above can probably
be best explained by the consideration that for the largest companies in
the sample holds, that the number of potential interesting patents that is
generated at a R&D-expenditures to sales ratio of around 13 percent is so
large that it requires an investment in the Development-process to such an
extend, that Discovery and by that the innovative potential, could become
at risk.
MANAGEMENT IMPACT
Provisionally the following practical implications for R&D-management can
be abstracted from the results presented in this paper.
I. The data suggest that the motivation of scientific staff is one of the
major success parameters, in terms of speeding up product development and
adjustment to market needs, in industrial pharmaceutical R&D. Because in a
flat organization like a R&D-laboratory, the possibilities for promotion in
terms of responsibility are limited, remuneration in terms of promotion on
the bases of scientific merits and other incentives for scientific staff
could be considered.
The necessary further concentration on fewer therapeutic areas could
lower the innovative potential. Therefore it might be considered to give
scientific staff in basic research the opportunity to spend part of their
time on promising research in areas of their own choice.
The data suggest that tight planning and evaluation are important
success parameters in industrial pharmaceutical R&D. Indeed the Development
process deserves strong coordination. However, the positive effect seems to
be at least partly lowered by too frequent meetings.
The data suggest that a minimum annual R&D-expenditure of around 200
million dollar is needed to keep up innovative Research and Development.
Above around 750 million dollar 'economies of scale' seem to appear in
pharmaceutical R&D.
For three of the larger companies in the sample the data suggest that
above R&D-expenditures of 12-15 percent of sales the companies has to put
so much effort in the Development process, especially in large scale
clinical trials, that Discovery and by that the innovative potential, could
become at risk.
It should be considered that the picture arising from this study is far
from complete, given the inherent limitations of a survey and the limited
number of companies analyzed. 	 However, the study supplies interesting
management concepts which could 	 be used as starting points for in depth
studies in individual companies.
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Fig.l. The industrial pharmaceutical R&D-process (double unit cell model)
P0 = the finding of the 'lead', chemical compound with assumed
therapeutic effect; P 1 = ' lead' with pharmacokinetic and
toxicological testing reports, start of clinical testing,
first on volunteers, later on patients; P, = submittance of
registration dossiers to the authorities; P, = registration and
launch; P4 = post marketing surveillance (post launch control
on side effects of drugs).
G = goal setting; A = accounting; C = communication; R =
research management; I = input; T = transformation; 0 = out-
put.
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Rapidity of resource allocation procedures (in months)
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Frequency of contacts with colleagues of other companies, scientists
and physicians on congresses (times per year)
Subjective assessment of the importance of short and middle range
planning and the intensity of evaluation by the main office
(higher values indicate a more positive perception)
World wide pharmaceutical sales in billion US dollar 1991
Number of patents of synthetic chemical compound with assumed
therapeutic efficacy submitted world wide from 1985 till 1991
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Table 2 The association of the different organizational and
managerial parameters with pharma sales (t-values'), between
brackets the associations with pharma sales if scale is
excluded from the model (N = 10 companies).
Predictor variables Association with pharma sales
t-value	 direction
Scale (R&D-exp.)	 15-22
	 positive
Structure	 *	 negative
Management control
Personnel control	 8-12 (13-14)	 positive
Resources control	 *	 negative
Communication
R&D-process comm.	 7-9 (6-9)
	 negative
External comm.	 *	 negative
Coordination	 5-6 (5-8)
	 negative
* parameter omitted because of low association with pharma
sales (t-value below 2.5).
1 t-value = mean partial derivative of criterion variable w.r.t. predictor variable x standard
deviation of predictor variable / standard deviation of residual error.
The range of the t-values presented in table 2 is based upon the results of five runs of the neural net-
work, using different model and test sets. The range of the R 2 of the different runs was as follows. If
scale is included in the model: R 2 model set = 85-92% and R 2 test set = 91-99%. One run provided less
reliable results (R2 model set = 69% and R 2 test set = 84%). The t-values were comparably lower, t=5 for
R&D-exp., t=4 for personnel control and t=2 for R&D-process communication and coordination. If scale is
excluded from the model the model and test set fits are lower: R 2 model set = 73-79% and R 2 test set =
61-63%, one run provided a test set fit of 89%.
